Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	9/2/2005 9:19:43 AM
	Read Replies (3) of 946

EDIT -- BTW that's not the Bianco we know and love. Are they related? SEATTLE, Sept. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ: CTIC; Nuovo Mercato) announced today that Grant Thornton resigned effective August 31, 2005 as the Company's independent auditor. There were no disagreements between CTI and Grant Thornton on any matter of accounting principles or practice, financial disclosure, or audit procedures. "We've had a good relationship with Grant Thornton and I am working with the Audit Committee to engage a new audit firm as soon as possible," stated Louis A. Bianco, Chief Financial Officer of CTI. About Cell Therapeutics, Inc. Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next